Because of their essentiality for DNA replication, transcription, and repair, type II topoisomerases are targets for antibacterial and anticancer drugs. There are two type II topoisomerases in humans, topoisomerase IIa (TOP2A) and topoisomerase IIb (TOP2B), and two in bacteria, gyrase and topoisomerase IV. Inhibition of one or both of the human type II topoisomerases by antibacterial compounds targeting their bacterial counterparts could result in toxicity. In addition, side effects of anticancer drugs targeting TOP2A could result from inhibition of TOP2B. A simple and rapid biochemical assay for the activity of TOP2A and TOP2B would be advantageous for screening for novel inhibitors, testing them for selectivity for one enzyme over the other, and testing for potential toxicity of antibacterial type II topoisomerases mediated by human topoisomerase II inhibition. In this paper, we show that a previously reported high-throughput, fluorescence anisotropy-based assay for ATP-dependent relaxation of supercoiled DNA by human TOP2A can also be used under identical conditions for human TOP2B. We used this assay to compare the potencies versus both enzymes of 19 compounds reported in the literature to inhibit human and/or bacterial type II topoisomerases. We also used the assay to investigate the effect of ATP concentration on inhibitor potencies.
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By making double-stranded breaks in the DNA backbone, passing another length of the DNA through the break, and then resealing it, type II topoisomerases (TopoIIs) 2 alter the degree of supercoiling of DNA in a process that requires ATP hydrolysis [1] . The essentiality of TopoIIs for cellular processes involving DNA such as replication, transcription, chromosome segregation, and recombination in both eukaryotes and prokaryotes [2] makes these enzymes attractive targets for both anticancer [3] and antibacterial drugs [4, 5] . For example, cancer chemotherapeutic epipodophyllotoxins such as etoposide target human TopoII, and the antibacterial fluoroquinolones such as ciprofloxacin target bacterial TopoIIs (gyrase and TopoIV). There is a need to identify new TopoII-targeting drugs with high specificity in order to reduce cytotoxic and genotoxic side effects.
Human cells have two TOP2 enzymes, TOP2A and TOP2B [6, 7] . They share 68% amino acid identity and 77% similarity [8] . TOP2A and TOP2B are expressed at similar levels in dividing cells, including tumors, whereas TOP2B is the more abundant TopoII in noncycling cells [9] . TOP2A is essential for survival of cells in vitro [10] . In contrast, TOP2B is not essential for cells in vitro [11] , but mice lacking TOP2B are not viable because TOP2B is important for neuronal differentiation [12, 13] . Murine Top2BÀ/À cells are resistant to the cytotoxicity of acridines and mitoxantrone [14] , and the genotoxicity of etoposide is TOP2B dependent [15] [16] [17] . Also, TOP2B is implicated in the cardiotoxicity of doxorubicin [18] . Consistent with this, inhibition of TOP2B by dexrazoxane (ICRF 187) is protective against doxorubicin cardiotoxicity [19] . Differential inhibition of TOP2A over TOP2B may therefore be a desirable property for novel anticancer drugs [16, 20] . Current agents against TopoII were not selected for isoform specificity. Some of these agents lack selectivity [21] [22] [23] while others have been reported to be selective inhibitors of one of the enzymes, including razoxane (ICRF 159), ICRF 193, and merbarone, which were more potent inhibitors in vitro of TOP2A [21, 24] , and XK469, which was a more potent inhibitor of TOP2B [25] .
It is becoming clear that there are differential cellular effects of inhibiting TOP2A and TOP2B isoforms in cells, so for future drug development it will be important to measure the potencies of novel TOP2-directed anticancer drugs toward both enzymes. It is also important to test for inhibition of TOP2A and TOP2B by novel antibacterial TopoII inhibitors because unintended inhibition of the human enzymes could cause side effects, including genotoxicity [15, 16, 26, 27] . It is desirable to make such measurements of TopoII inhibition using purified topoisomerase enzymes to simplify the interpretation of inhibitor potencies.
Measurements of purified TopoII activity typically involve using gel electrophoresis to separate DNA topoisomers, either plasmids differing in their degree of supercoiling or single versus concatenated kinetoplast DNA circles (decatenation). This low-throughput method is not suitable either for high-throughput screening for novel TopoII inhibitors or for convenient measurement of inhibitory potencies for many compounds simultaneously. A simple and convenient high-throughput method using a fluorescence anisotropy measurement in microtiter plates has been described previously for measuring supercoiling of relaxed plasmid DNA by gyrase [28] or ATP-dependent relaxation of supercoiled plasmid DNA by TOP2A [29] . This method, performed in homogeneous solution, requires only addition of reagents to the wells of the plate, without heating, washing, or filtration, followed by measurement with a fluorescence polarization-equipped plate reader. Another highthroughput-compatible topoisomerase assay was recently reported [30] .
In this paper, we show that the high-throughput fluorescence anisotropy-based assay for ATP-dependent relaxation of supercoiled DNA previously described for activity measurements of purified human TOP2A [29] can also be used under identical conditions for purified human TOP2B. We were therefore able to perform, in just a few hours, a side-by-side comparison of inhibitory potencies toward TOP2A-and TOP2B-catalyzed ATP-dependent supercoiled DNA relaxation for a set of 19 diverse TopoII inhibitors, including both catalytic inhibitors and topoisomerase poisons, as well as for a set of 75 analogs of a novel inhibitor of bacterial type II topoisomerases. In addition, we investigated the effect of ATP concentration on the potencies of some of the inhibitors toward TOP2B, novel information that contributes to investigations of the mechanisms of inhibitors with respect to the topoisomerase catalytic cycle.
Materials and methods

Chemicals
Commercially available inhibitors were purchased from Sigma (St. Louis, MO), except for gemifloxacin and teniposide, which were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Proprietary compounds were prepared by AstraZeneca. Compounds were dissolved in dimethyl sulfoxide (DMSO) at 10 or 20 mM. Stock solutions were stored at À20°C.
Enzymes
Human TOP2A was purchased from Affymetrix/USB Corp. (Cleveland, OH). Human TOP2B was purified as previously described [31] .
Fluorescence anisotropy assay for ATP-dependent relaxation of supercoiled plasmid DNA, IC 50 measurements, and calculations Two-fold serial dilutions of compounds were prepared in DMSO. Two overlapping sets of serial dilutions of each compound were present on each replicate plate, with final concentrations in the assays ranging from 200 lM to 0.39 lM and from 2 lM to 3.9 nM, except that for gemifloxacin and levofloxacin, the concentration ranges were twice as high. The final DMSO concentration in the assays was 2% by volume. The assay conditions, methods, plate reader settings, and calculations were described previously [29] . All measurements were made at room temperature, about 21°C. Inhibitors and enzymes were incubated together for 30 min at 2Â their final concentrations prior to initiation of the reactions with a solution of ATP and DNA at 2Â their final concentrations. The TOP2B concentration in the assay was 90 ng/ml (0.5 nM monomer). TOP2A and TOP2B assays were performed at the same time using replicate assay plates. A third replicate plate was used for interference correction [32] . Data points were excluded from IC 50 curve fitting analysis if the correction procedure necessitated a greater than 2-fold change in the value of a measurement. When IC 50 s fell within the ranges of both sets of dilutions, the average IC 50 was calculated. Measurements were made on 3 separate days. The maximal range of triplicate IC 50 measurements was 3-fold (highest/lowest IC 50 ), and the maximum percentage coefficient of variation (100 Â standard deviation/mean) was 64%.
Each plate containing enzyme had 32 wells with no enzyme or inhibitor (MIN) and 32 wells with enzyme but no inhibitor (MAX). The DMSO concentration was 2% by volume in MAX and MIN wells. The average MIN and MAX for each plate were used to calculate percentage inhibition. Plate-wise Z 0 scores [33] were 0.74 ± 0.06 for TOP2A and 0.77 ± 0.04 for TOP2B (mean ± standard deviation, n = 6). The average anisotropy difference between plate-averaged MAXs and MINs was 0.10 ± 0.01 for both TOP2A and TOP2B (mean ± standard deviation, n = 6).
Apparent K m (ATP) of TOP2B
To measure the apparent K m (ATP) of TOP2B at the concentration of supercoiled DNA used in the fluorescence anisotropy assay, the ATP concentration was varied between 1 and 2000 lM and the TOP2B concentration was varied between 45 and 720 ng/ml. Controls were included that omitted ATP or TOP2B. All other conditions were the same as above. ATP concentration had no effect on the baseline anisotropy in the absence of TOP2B, and TOP2B concentration had no effect on the baseline anisotropy in the absence of ATP. From the set of measurements of anisotropy change (Danisotropy) made at each ATP concentration over a range of TOP2B concentrations, the result was chosen that had the highest Danisotropy in the range 0.01 to 0.10. These values were divided by their respective TOP2B concentrations to obtain the measurements of initial rates, expressed as Danisotropy/(ng/ml TOP2B). The data were fit to the Michaelis-Menten equation by nonlinear least-squares regression to obtain K m,apparent (ATP).
Effect of ATP concentration on TOP2B inhibitor IC 50 s
Compound concentrations ranged from 20 to 0.039 lM, except for gemifloxacin, for which the range was 400 to 0.78 lM. The ATP and TOP2B concentrations were varied in parallel to give Danisotropy % 0.08-0.10 and were as follows: 20 lM ATP with 720 ng/ml TOP2B, 100 lM ATP with 130 ng/ml TOP2B, and 1000 lM ATP with 70 ng/ml TOP2B. Other conditions used were the same as stated previously. Assays with each pair of ATP and TOP2B concentrations were performed on separate plates. An additional plate was included with no ATP or TOP2B for use in artifact correction.
Results
Titration of human TOP2B concentration in the fluorescence anisotropy assay
The ATP-dependent relaxation of supercoiled plasmid DNA by human TOP2B was measured using the same assay and under the same conditions as previously reported for human TOP2A [29] . The fluorescence anisotropy readout increased in direct proportion to the TOP2B concentration for enzyme concentrations up to 100 ng/ml (0.56 nM monomer, molecular weight 180,000), consistent with previous demonstrations that the change in fluorescence anisotropy is directly proportional to the change in the fraction of the plasmid that is relaxed [28] . There was no anisotropy change when ATP was omitted, showing that plasmid relaxation was not due to contaminating endonuclease activity (Fig. 1) . At 1000 ng/ml TOP2B in the absence of ATP, the anisotropy increased by 0.01 (not shown), showing that contaminating endonuclease activity or background cleavable complex stabilization was negligible under typical assay conditions. The assay provided a usefully large anisotropy change of 0.1 and a satisfactory Z 0 > 0.7 when the TOP2B concentration was 90 ng/ml. The correspondence between the fluorescence anisotropy and the degree of supercoiling as measured by gel electrophoresis was demonstrated previously [28] .
Potency of human TOP2A and TOP2B inhibition by compounds
The concentrations of a diverse set of 19 commercially available TopoII inhibitors causing 50% inhibition (IC 50 ) of TOP2A and TOP2B activity in the fluorescence anisotropy-based assay of ATP-dependent supercoiled DNA relaxation were measured side-by-side (Table 1). The IC 50 s were reproducible from day to day. Although some compounds caused interference in the assay due to compound fluorescence (daunorubicin, doxorubicin, and epirubicin) or fluorescence quenching (amsacrine, actinomycin D, and most severely, mitoxantrone), it was possible to calculate IC 50 s for every compound tested. The TOP2A IC 50 values of amsacrine, ICRF-193, merbarone, mitoxantrone, suramin, teniposide, and etoposide were in agreement with those previously reported using the same assay [29] .
The anthracyclines daunorubicin, doxorubicin, and epirubicin had nearly identical IC 50 s, which were slightly but consistently more potent against TOP2B than TOP2A. The difference was statistically significant (P < 0.05) for daunorubicin and doxorubicin. For both of the epipodophyllotoxins, etoposide and teniposide, the TOP2B IC 50 s were about 2-fold less potent than the TOP2A IC 50 s, although the differences did not quite reach statistical significance. Teniposide was more potent than etoposide. Merbarone was 4-fold more potent versus TOP2A than TOP2B, a difference that was statistically significant. ICRF-193, in contrast was 2-fold more potent versus TOP2B than TOP2A, a difference that was also statistically significant. Although mitoxantrone was 2-fold more potent versus TOP2B than TOP2A, the difference did not reach statistical significance. None of the other compounds (razoxane, dexrazoxane, amsacrine, actinomycin D, suramin, genistein, bisantrene, XK469, ciprofloxacin, gemifloxacin, or levofloxacin) showed as much as a 2-fold potency difference between the two enzymes, although the slight difference between TOP2A and TOP2B IC 50 s of levofloxacin was statistically significant. That the inhibition by merbarone, actinomycin D, and bisantrene may have been nonspecific due to compound aggregation or insolubility is suggested by the very steep, step-like shapes of their IC 50 curves (not shown). For merbarone, this may only have been the case with TOP2B, since the TOP2A IC 50 curve was less steep.
The percentage inhibition vs compound concentration IC 50 curves increased monotonically from 0 to 100% inhibition for all the compounds for which compound interference in the assay was inconsequential (data not shown). If there had been a significant detection of cleavable complex stabilization in the assay, it would have resulted in inhibitor-induced DNA relaxation caused by linearization of the plasmid, rather than the observed inhibition of relaxation. There would, therefore, have been no apparent inhibition by the topoisomerase poisons, or IC 50 curves that showed partial inhibition and a return to no inhibition at high inhibitor concentrations, or enhancement of relaxation rather than inhibition. Since no such phenomena were observed, we conclude that the assay does not detect cleavable complex stabilization to a measurable extent.
Apparent K m (ATP) of TOP2B
The apparent K m (ATP) for DNA relaxation by TOP2B in the fluorescence anisotropy assay, which contains 85 lg/ml DNA Fig. 1 . The effect of human TOP2B concentration on ATP-dependent relaxation of supercoiled plasmid as measured by the increase in fluorescence anisotropy. Assay conditions were as described in [29] , except for the substitution of TOP2B for TOP2A. The DMSO concentration was 2% by volume. Data points and error bars represent the means and standard deviations of triplicate measurements. substrate, was 0.17 ± 0.03 mM (see Fig. 2 ), similar to the value of 0.21 ± 0.04 mM obtained previously for TOP2A in the same assay under identical conditions [29] . There was no evidence of the sigmoidal response to ATP reported by Drake et al. [24] . K m (DNA) was not investigated.
Effect of ATP concentration on TOP2B inhibitor IC 50 s
The effect of varying the ATP concentration from well below to well above the K m,apparent (ATP) in the fluorescence anisotropy assay on the IC 50 s of the more potent examples of TOP2B inhibitors is shown in Table 2 . For some compounds, there was no significant effect of ATP concentration on IC 50 . These include the anthracyclines daunorubicin, doxorubicin, and epirubicin, as well as suramin, gemifloxacin, actinomycin D, and bisantrene. For some compounds, there was a substantial decrease in IC 50 as ATP increased. These include the bisdioxopiperazines dexrazoxane (P9.3-fold lower IC 50 at 1000 lM ATP than at 20 lM ATP), razoxane (5.6-fold), and ICRF-193 (6.6-fold), XK469 (P5.4-fold), and teniposide (5.2-fold). Smaller ATP-dependent decreases in IC 50 were seen for amsacrine (2.3-fold) and genistein (2.5-fold). For mitoxantrone, an ATP-dependent IC 50 decrease was suggested, but interference by the compound prevented measurement of the highest IC 50 at 20 lM ATP.
Comparison of TOP2A and TOP2B IC 50 s for a set of bacterial type II topoisomerase inhibitors analogs
As a demonstration of the practical application of the fluorescence anisotropy assay, TOP2A and TOP2B IC 50 s were measured in a side-by-side assay for 75 related proprietary compounds from a bacterial type II topoisomerase inhibitor project. Fig. 3 shows that there was a strong correlation between the TOP2A and the TOP2B IC 50 s, with slightly more potent inhibition of TOP2B than TOP2A overall (average TOP2A-to-TOP2B IC 50 ratio = 1.9, standard deviation = 0.7, n = 52 measurements for which both the TOP2A and the TOP2B IC 50 s were <200 lM).
Discussion
The above results demonstrate the use of a simple, highthroughput assay to simultaneously and quickly measure the potencies of numerous inhibitors toward both human TOP2A-and TOP2B-catalyzed ATP-dependent relaxation of supercoiled DNA. The unique nature of the fluorescence anisotropy assay is its speed, simplicity, and convenience compared with the usual method, agarose gel electrophoresis, allowing measurement of IC 50 s versus both TOP2A and TOP2B at the same time for a large number of inhibitors with little effort. This was done for 19 compounds in triplicate (Table 1) , i.e., 114 IC 50 s, which were measured in half a day by one person, including calculations, using nine 384-well assay plates. The same amount of effort was required to measure, at one time, the 150 IC 50 s shown in Fig. 3 . To do this by agarose gel electrophoresis would have required 57 or 75 gels, respectively (2 IC 50 s/gel), with samples loaded manually. Each gel takes a minimum of 3 h to run, although several gels can be run in parallel and the electrophoresis can be run overnight, plus additional time is needed to stain and destain the gels. Band quantitation is a laborious manual process done one lane at a time. The data in Table 1 would take one person at least a week to collect by gel electrophoresis and would be extremely labor-intensive. The gelbased assay could not be scaled up to screen large compound libraries.
It has been proposed that selective inhibition of TOP2A over TOP2B would be preferable for anticancer drugs because TOP2B mediates cytotoxicity [14, 18] and genotoxicity [15] [16] [17] . The small differences (64-fold) observed between TOP2A and TOP2B IC 50 s of the compounds we tested, presumably due to the high degree of sequence similarity between the isoforms, suggest that it will be challenging to identify compounds with high isoform selectivity. An assay method such as the one described here would assist in the effort by maximizing the number of compounds that could be screened for differential inhibition in anticancer drug discovery programs to develop a structure-activity relationship (SAR) for the greatest degree of selective inhibition of one of the two enzymes. This methodology could also add value to an antibacterial drug discovery program, especially one targeting bacterial TopoIIs, by enabling facile testing of all the compounds in a series for unwanted inhibition of human TopoII enzymes that could lead to cytotoxic and/or genotoxic side effects. The data in Fig. 3 for a series of 75 related proprietary bacterial TopoII inhibitors show that compounds within the series cover a wide range of TOP2A and TOP2B inhibitory potencies, and that these potencies are highly correlated.
Because of the high degree of sequence homology between human TOP2A and TOP2B [8] , it is not surprising that there was little difference between the inhibitory potencies of the compounds tested toward the two enzymes in vitro. The largest IC 50 ratio was 4-fold. The fact that the IC 50 s varied over a 10,000-fold range shows that the small differences between TOP2A and TOP2B IC 50 s for individual inhibitors were not the result of a lack of dynamic range of the assay for IC 50 measurement. Moreover, the high correlation between IC 50 s measured by the TOP2A fluorescence anisotropy assay and the gel-based assay [29] shows that the fluorescence anisotropy assay has the same ability to differentiate between inhibitor potencies as the gel-based assay. There may be certain modes of inhibition of the enzymes that are more likely to produce differential inhibitor potency due to greater sequence divergence. The C-terminus is the most divergent region between TOP2A and TOP2B, affecting DNA binding by TOP2B but not TOP2A [34] . Therefore compounds binding at the C-terminus might have the greatest likelihood of being selective. The C-terminal domain of TOP2A but not TOP2B is essential for growth of yeast in which the natural TopoII has been replaced by one of the human enzymes [35] . Sequence divergence between the C-terminal domains might therefore make the TOP2A C-terminal domain a promising target for anticancer drugs with low TopoII-related toxicity.
The ATP-dependent supercoiled DNA relaxation IC 50 s measured here for doxorubicin and daunorubicin, mitoxantrone, bisantrene, suramin, and merbarone were quite similar to those reported by Perrin et al. [21] for inhibition of DNA decatenation by both TOP2A and TOP2B. Also, the potency and TOP2A selectivity of merbarone we observed were similar to previous findings [22, 24] . On the other hand, there were several discrepancies between our IC 50 results and those reported elsewhere. Perrin et al. [21] reported a high degree of selectivity of razoxane and ICRF-193 for TOP2A, which we did not observe. Perrin et al. [21] also reported much higher IC 50 s for etoposide, teniposide, genistein, amsacrine, and dexrazoxane than we measured. The IC 50 of XK469 was much higher and the selectivity for TOP2B much greater in the report by Gao et al. [25] than we observed. The IC 50 s we measured for ciprofloxacin and levofloxacin were much lower than previously reported values [36] . To some extent, these differences may be due to the measurement of different phenomena: ATP-dependent relaxation of supercoiled DNA versus decatenation of linked circles [21, 24] . Topoisomerase poisons are represented among those compounds for which our results are in agreement with the literature (anthracyclines, mitoxantrone, bisantrene) and those compounds for which our results differ (epipodophyllotoxins, genistein, amsacrine, XK469, fluoroquinolones). Therefore, it is unlikely that the discrepancies arise from an inability of our assay to correctly measure inhibition of DNA relaxation by topoisomerase poisons. As already stated, our assay is capable of measuring IC 50 s over a wide dynamic range. Therefore, the smaller TOP2A vs TOP2B IC 50 differentials we measured for some compounds than have been previously reported are not due to the inability of the assay to detect them. Differences in assay conditions that may affect the ionization state of some compounds and the target site as well as compound solubility, such as substrate concentrations, pH, and Mg 2+ concentration, may also contribute to the discrepancies. DNA concentration differences between assays could have substantial effects on potencies of compounds that bind to DNA, such as the anthracyclines. It is important, therefore, that IC 50 s for TOP2A and TOP2B inhibition are measured under identical conditions, as was the case for our measurements.
Interference by chemical compounds with biochemical assays is frequently observed. Some compounds, referred to as promiscuous inhibitors, form aggregates that inhibit enzyme activity, causing false positives [37, 38] . Compound autofluorescence, fluorophore quenching, and absorption of light by compounds introduce error into measurements of inhibitor potency when the compound remains in the well of the assay plate during the readout [32] , as in the case of the assay described here. The methods for identifying false positives caused by compound aggregation and of correcting for errors caused by interference with the readout have been described previously [32, 37, 38] . Identification of false positives caused by compound aggregation requires increasing the enzyme concentration and including 0.01% Triton X-100 detergent, which is likely to be feasible for the TOP2A and TOP2B fluorescence anisotropy assays. The interference correction procedure was used for the compound IC 50 measurements in this paper. The assay has a satisfactory signal-to-noise ratio for screening purposes, as measured by Z 0 score >0.7 (see Materials and methods), although no information is currently available regarding the rate of false positives and the extent of detection interference when screening a large compound collection with this assay. Detection of promiscuous inhibition by increasing the topoisomerase concentration, which would require simultaneously decreasing the reaction time, is likely achievable with the fluorescence anisotropy assay. Addition of 0.01% Triton X-100 to the TOP2B fluorescence anisotropy assay to counteract promiscuous inhibition is also likely to be achievable, since it had no effect on the TOP2A concentration response in the same assay [29] . Thus the fluorescence anisotropy assay is expected to be adaptable to the use of previously described high-throughput tools to identify false positives from screens of compound libraries.
The ability of the fluorescence anisotropy assay used here to tolerate variation in the ATP concentration enabled us to measure the apparent K m (ATP) for DNA relaxation by TOP2B under the same conditions as we previously measured this parameter for TOP2A [29] . The value was approximately the same at about 0.2 mM for both enzymes, which is consistent with their high degree of sequence identity.
Investigations into the mechanisms of inhibition by TOP2A and TOP2B inhibitors can make use of the ability to vary the ATP concentration in the fluorescence anisotropy assay by measuring the effect of ATP concentration on inhibitor potency. Of the inhibitors we tested, several responded to an increase in ATP concentration with an increase in potency (decrease in IC 50 ). These included the bisdioxopiperazine catalytic inhibitors dexrazoxane, razoxane, and ICRF-193. These non-DNA-intercalating, symmetrical compounds bind to a part of the interface between TOP2 subunits that is present only when ATP or ADP is bound, the ''closed clamp'' conformation [39] . Thus the ATP-dependent enhancement of the potency of these compounds in the fluorescence anisotropy assay is a reflection of their mechanism of action. Interestingly, although the effect of bisdioxopiperazines on the ATPase activity of type II topoisomerases has been investigated [40, 41] , the effect of ATP concentration on the inhibitory potency of these compounds has not been reported. Suramin, which blocks DNA binding to the enzyme [42] , showed little effect of ATP on its IC 50 , consistent with its mode of inhibition.
Since the formation of enzyme-linked DNA with a doublestranded break (''cleavable complex'') by type II topoisomerase is enhanced by ATP [43] [44] [45] , it might be expected that the potencies for inhibition of ATP-dependent supercoiled DNA relaxation for compounds that stabilize the cleavable complex (''topoisomerase poisons''), such as anthracyclines, epipodophyllotoxins, bisantrene, mitoxantrone, actinomycin D, amsacrine, XK469, genistein, and gemifloxacin would increase as the ATP concentration increased. Interestingly, this was not the case for the anthracyclines, bisantrene, gemifloxacin, and actinomycin D (Table 2) , the IC 50 s of which for inhibition of TOP2B-catalyzed supercoiled DNA relaxation showed a negligible response to the ATP concentration. In contrast, the expected IC 50 decreases with increasing ATP concentration occurred for amsacrine, teniposide, genistein, and XK469. Mitoxantrone may also have become more potent with increasing ATP concentration, but this intensely colored compound interfered with the fluorescence anisotropy assay such that the effect could not be well measured.
The ability quickly to measure the ATP dependence of the inhibitory potency of several compounds simultaneously enables the fluorescence anisotropy assay to facilitate the discernment of subtle distinctions between the mechanisms of TOP2 inhibitors. The assay could thereby contribute to an improved understanding of the mechanisms of TOP2 inhibitors and of the enzymes as well. However, inhibition of TopoII-catalyzed ATP-dependent relaxation of supercoiled DNA is caused by both topoisomerase poisons and catalytic inhibitors. Cytotoxicity can result from both topoisomerase poisoning and catalytic inhibition, whereas genotoxicity is thought to result mainly from topoisomerase poisoning. Moreover, catalytic inhibition can be protective against the toxicity of topoisomerase poisons [19] . Therefore, measuring only inhibition of catalysis cannot by itself distinguish between compounds that are genotoxic due to TopoII poisoning and those that are not, or identify compounds that are protective against the toxic effects of topoisomerase poisons. A goal for the future should be the development of a high-throughput assay for cleavable complex stabilization. The two assays used together would be a powerful tool for characterizing the modes of TopoII inhibition of large numbers of compounds.
